Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
Transaction summary
Metric Value Shares traded 19,137 Transaction value $3.13 million, as reported in the SEC Form 4 filing dated July 18, 2025 1-year performance (as of July 18) 8% total return over the past year (calendar year basis)
Key questions
How does this transaction compare to John C. Reed's historical trading activity?
This sale is smaller than Reed's historical median transaction size of 36,239 shares, and follows a recent trend of reduced trade volumes and more frequent selling over the past year, with only 20% of his trades classified as buys over the past 12 months.
How does the transaction price relate to current market pricing?
Shares were sold at an average price of $163.55, approximately 0.5% below the $164.36 closing price as of July 21, 2025, indicating the sale occurred at a slight discount to the latest market price.
What is the context of this transaction in relation to Johnson & Johnson's recent performance?
Johnson & Johnson shares delivered 8% total return in one year as of the transaction reporting date. The company maintains a large market capitalization and leadership in the healthcare sector, suggesting the sale does not coincide with pronounced negative price momentum.
Company overview
Metric Value Market capitalization $417.4 billion Revenue (TTM) $90.6 billion Net income (TTM) $22.7 billion Dividend yield 3.0%
Company snapshot
Johnson & Johnson generates revenue through two segments: innovative medicine (pharma) and medtech (medical devices).
The company operates a diversified business model focused on research, development, manufacturing, and global distribution of healthcare products, with a balanced mix of prescription medicines and medical devices.
Johnson & Johnson is a Dividend King, having increased its dividend for over 60 consecutive years.
Foolish take
Once known primarily for its consumer health brands such as Tylenol and Listerine, Johnson & Johnson made a major strategic move in 2023 when it spun off its consumer health business into a separate publicly-listed company, Kenvue. J&J is now a healthcare behemoth, with two diversified businesses that cover two of the most important areas of healthcare.
Its innovative medicine segment focuses on oncology, immunology, and neuroscience, owns top medicine brands like Darzalex, Stelara, and Imbruvica, and accounted for 64% of J&J's total sales in fiscal 2024. Medtech, meanwhile, makes medical equipment and technologies for cardiology, surgery, and vision. Between the two businesses, J&J owns 26 products or platforms generating over $1 billion in annual sales each.
Despite Stelara's loss of exclusivity, J&J continues to deliver. In its second quarter, J&J reported 5.8% growth in net sales. In innovative medicine, oncology continues to grow at a steady pace, while Spravato is growing rapidly. Sales from Spravato, a nasal spray for treatment-resistant depression in adults, jumped 53% in Q2.
Strong Q2 performance and progress in new product pipeline even encouraged J&J management to boost its full-year guidance. It now expects operational sales (sales excluding the impact of currency) to grow by 4.8% at the midpoint versus its previous forecast of 3.8% and adjusted earnings per share by 8.7% at the midpoint versus 6.2%. I believe investors shouldn't read much into insider sales like Reed's transaction, and continue to buy and hold this magnificent dividend stock.
Glossary
Form 4: A required SEC filing disclosing insider trades by company officers, directors, or major shareholders.
Open market sale: The sale of securities on a public exchange, rather than through private transactions or company programs.
Insider trading activity: Buying or selling a company's stock by its executives, directors, or employees with access to nonpublic information.
Median transaction size: The middle value of all transaction sizes, used to measure typical trade volume for an individual.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
Dividend yield: Annual dividend payments divided by the stock's current price, shown as a percentage.
TTM: The 12-month period ending with the most recent quarterly report.
Market capitalization: The total market value of a company's outstanding shares.
Pharmaceuticals: Prescription drugs and medicines developed, manufactured, and sold by healthcare companies.
Medtech: Medical technology products, including devices and equipment used in healthcare settings.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,060%* — a market-crushing outperformance compared to 182% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor.
See the stocks »
*Stock Advisor returns as of August 11, 2025
Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
29 minutes ago
- National Post
Canadians' view of leadership in Washington plunges: Gallup poll
In the wake of a stormy stretch in Canada-U.S. relations, the Canadian view of American leadership has plummeted. Article content Gallup's latest survey of Canadian opinion, conducted in May and June, found approval of Washington slipping to 15 per cent, statistically in line with sentiment when Donald Trump was president the first time. Article content Article content Canadian opinion of leaders in Washington has fluctuated over time, showing a clear connection with who is sitting in the White House. For example, Canadian approval of American leadership averaged 61 per cent under Barack Obama, compared with 19 per cent in Trump's first term and 41 per cent under Joe Biden. Article content Aside from an uptick in 2021, only a minority of Canadians have approved of Washington since 2017. Article content Article content The latest downturn comes in the midst of diplomatic and trade tensions. Since returning to the White House, Trump has introduced high tariffs and continued with rhetoric suggesting Canada should become the '51st state.' Article content Gallup asked about four global powers during it recent World Poll. Germany's leadership received the most positive ratings from Canadians. A slim majority of Canadians (54 per cent) approve of Berlin. Article content Canadians have a higher approval rating for Beijing than they do for Washington. It sits at 23 per cent, up eight points from last year's poll. Article content Otherwise, the 79 per cent of Canadians who disapprove of U.S. leadership is statistically close to the 82 per cent who disapprove of Russia's. Article content Meanwhile, Canadians' view of their own leadership has improved considerably, rising 19 points from last year to 59 per cent now. The increase followed Mark Carney replacing Justin Trudeau as Liberal party leader and prime minister in March and his election victory in April. Article content Article content Approval of Trudeau fell from 64 per cent in 2016 — his first full year in office — to a low of 40 per cent in 2024. Article content Article content However, Canadians are gloomy about the state of the economy. Their optimism dropped to a new low in 2025, with 27 per cent saying their local economy is getting better, compared to 63 per cent who think it's getting worse. Article content The share of Canadians who say it's a good time to find a new job has fallen sharply down from 74 per cent in 2022 to 32 per cent in 2025. This is the lowest level of job optimism since the COVID-19 pandemic started in 2020 and the 2009 financial crisis. Article content The housing affordability crisis also remains widespread in Canada. One in four adults are satisfied with the availability of good, affordable housing, compared with 72 per cent who are dissatisfied. Article content Weak economic sentiment poses a test for Carney, says the folks at Gallup. 'Sustaining public support may depend on whether his administration can reverse declining optimism and navigate a complicated relationship with Washington.' Article content
National Post
29 minutes ago
- National Post
RioCan Real Estate Investment Trust Announces August 2025 Distribution
Article content TORONTO — RioCan Real Estate Investment Trust ('RioCan') (TSX: today announced a distribution of 9.65 cents per unit for the month of August. The distribution will be payable on September 8, 2025, to unitholders of record as at August 29, 2025. Article content About RioCan Article content Article content RioCan meets the everyday shopping needs of Canadians through the ownership, management and development of necessity-based and mixed-use properties in densely populated communities. As at June 30, 2025, our portfolio is comprised of 178 properties with an aggregate net leasable area of approximately 32 million square feet (at RioCan's interest). To learn more about us, please visit Article content Article content Article content
Globe and Mail
29 minutes ago
- Globe and Mail
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog,
